NOVO NORDISK A/S NOVO NORDISK: FIRE AT KALUNDBORG SITE HAS NO IMPACT ON EXISTING PRODUCTION
Novo Nordisk: Fire At Kalundborg Site Has No Impact On Existing…
May 16, 2024 at 09:26 am EDT
Share
Share
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 927.3 DKK | +1.13% |
|
-0.16% | +32.83% |
| May. 31 | Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment | MT |
| May. 30 | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.83% | 598B | |
| +40.73% | 739B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk: Fire At Kalundborg Site Has No Impact On Existing…
